Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jun 1;109(1-3):20-9.
doi: 10.1016/j.drugalcdep.2009.11.023. Epub 2010 Jan 25.

Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence

Keith G Heinzerling  1 , Aimee-Noelle Swanson, Soeun Kim, Lisa Cederblom, Ardis Moe, Walter Ling, Steven Shoptaw
Affiliations
Randomized Controlled Trial

Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence

Keith G Heinzerling et al. Drug Alcohol Depend. .

Abstract

Objective: To compare modafinil to placebo for reducing methamphetamine (MA) use, improving retention, and reducing depressive symptoms and MA cravings. Rates of adverse events and cigarette smoking with modafinil versus placebo were also compared.

Methods: Following a 2-week, non-medication lead-in period, 71 treatment-seeking MA-dependent participants were randomly assigned to modafinil (400mg once daily; N=34) or placebo (once daily; N=37) for 12 weeks under double-blind conditions. Participants attended clinic thrice-weekly to provide urine samples analyzed for MA-metabolite, to complete research assessments, and to receive contingency management and weekly cognitive behavioral therapy (CBT) sessions.

Results: There were no statistically significant effects for modafinil on MA use, retention, depressive symptoms, or MA cravings in pre-planned analyses. Outcomes for retention and MA use favored modafinil in a post hoc analysis among participants with low CBT attendance and among participants with baseline high-frequency of MA use (MA use on >18 of past 30 days), but did not reach statistical significance in these small subgroups. Modafinil was safe and well tolerated and did not increase cigarette smoking.

Conclusions: Modafinil was no more effective than placebo at 400mg daily in a general sample of MA users. A post hoc analysis showing a trend favoring modafinil among subgroups with baseline high-frequency MA use and low CBT attendance suggests that further evaluation of modafinil in MA users is warranted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study participant flow chart
Figure 2
Figure 2
Proportion of participants with methamphetamine (MA) metabolite- free urine drug screens during the two week baseline period (b1, b2) and 12 week medication treatment period (t1–t12) in the total sample, and separately for participants with baseline lower frequency (18 or fewer of the past 30 days) versus higher frequency (more than 18 of the past 30 days) MA use and low CBT attendance (0–2 sessions) versus high CBT attendance (3 or more sessions).
Figure 3
Figure 3
Survival analysis depicting the proportion of participants retained in each treatment condition (modafinil versus placebo) throughout the 36 study visits (12 weeks) in the total sample, and separately for participants with baseline lower frequency (18 or fewer of the past 30 days) versus higher frequency (more than 18 of the past 30 days) methamphetamine (MA) use and low CBT attendance (0–2 sessions) versus high CBT attendance (3 or more sessions).
Figure 3
Figure 3
Survival analysis depicting the proportion of participants retained in each treatment condition (modafinil versus placebo) throughout the 36 study visits (12 weeks) in the total sample, and separately for participants with baseline lower frequency (18 or fewer of the past 30 days) versus higher frequency (more than 18 of the past 30 days) methamphetamine (MA) use and low CBT attendance (0–2 sessions) versus high CBT attendance (3 or more sessions).
See this image and copyright information in PMC

References

    1. Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, Smith EV, Kahn R, Chiang N, Vocci F, Ciraulo D, Dackis C, Roache JD, Salloum IM, Somoza E, Urschel HC, 3rd, Elkashef AM. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009;104:133–139. - PMC - PubMed
    1. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003–2017. - PubMed
    1. Batki S, Moon J, Delucchi K, Hersh D, Bradley M, Aguillon-Doms C, Mendelson J, Jones R, Panganiban T, Everhart T, Mengis M, Smolar S, Helmke H, Jacob P., III Amlodipine treatment of methamphetamine dependence, a controlled outpatient trial: preliminary analysis. The 63rd Annual Scientific Meeting of the College on Problems of Drug Dependence; Scottsdale, AZ. 2001.
    1. Batki SL, Moon J, Bradley M, Hersh D, Smolar S, Mengis M, Delucchi K, Sexe D, Bennett S, Lefkowitz E, Chu W, Morello L, Jacob P, III, Jones RT. Fluoxetine in methamphetamine dependence-a controlled trial: preliminary analysis. The 61st Annual Scientific Meeting of the College on Problems of Drug Dependence, Acapulco; Mexico. 1999.
    1. Bodenmann S, Xu S, Luhmann UFO, Arand M, Berger W, Jung HH, Landolt HP. Pharmacogenetics of Modafinil After Sleep Loss: Catechol-O-Methyltransferase Genotype Modulates Waking Functions But Not Recovery Sleep. Clin Pharmacol Ther. 2009;85:296–304. - PubMed

Publication types

MeSH terms